Erythrodermic psoriasis successfully and rapidly treated with brodalumab: Report of two cases

Dermatol Ther. 2020 Nov;33(6):e14351. doi: 10.1111/dth.14351. Epub 2020 Oct 10.


Erythrodermic psoriasis (EP) is a rare form of the disease clinically characterized by a generalized erythema covering ≥90% of the body surface area (BSA). The management of EP is challenging: no standardized guidelines exist with literature suggesting cyclosporine or infliximab as first-line therapy. However, a recent systematic review showed a positive response in EP patients treated with biologic agents. The most common biologic used for EP up until now has been ustekinumab, whereas infliximab might represent a first-line option in case of complicated EP (acute, severe, or unstable). Up until now, no case of brodalumab (a monoclonal antibody blocking IL-17 receptor) treatment for EP in real-life has ever been described. Here, we report the first two cases of efficacy and safety of brodalumab in real-life cases of EP.

Keywords: brodalumab; erythrodermic psoriasis; psoriasis.

Publication types

  • Case Reports

MeSH terms

  • Antibodies, Monoclonal, Humanized
  • Dermatologic Agents* / adverse effects
  • Humans
  • Psoriasis* / diagnosis
  • Psoriasis* / drug therapy
  • Treatment Outcome
  • Ustekinumab


  • Antibodies, Monoclonal, Humanized
  • Dermatologic Agents
  • brodalumab
  • Ustekinumab